Dr. Guoren Zhou 周国仁
Chief Physician
Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of malignant tumors, including lung, breast, gastric, esophageal, and colorectal cancer.
Dr. Zhou holds a master’s degree in oncology from Guangzhou Medical University (2005) and a doctorate from Nanjing Medical University (2018). The doctor has extensive clinical experience in diagnosing and treating common malignancies. Dr. Zhou has published nearly 30 papers on lung cancer research, with more than 10 indexed in SCI.
Professional roles
- Standing Committee Member, Tumor and Immunology Committee, Chinese Research Hospital Association
- Member, Oncology Branch, China Association of Integrative Medicine
- Standing Committee Member, Abdominal Tumor Committee, China Medical Education Association
- Member, Tumor Recurrence and Metastasis Professional Committee, Jiangsu Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhou Guoren). Papers usually list the name as Guoren Zhou or Zhou G.
Selected publications
103 papers on PubMed matched by name and affiliation; 21 as first or senior author since 2016. Most recent first- or senior-author papers:
- Tissue Cell, 2026 (senior author): Ablation of ASF1B mitigates the proliferation of A549 cells and enhances anti-PD-L1 therapy by regulating ferroptosis. PubMed 42114389
- Adv Sci (Weinh), 2026 (senior author): FTSJ3-Mediated 2'-O-Methylation of HSPA5 mRNA Stabilizes BOP1 via SUMOylation to Drive DRP1-Dependent Mitochondrial Fission and Fatty Acid Oxidation in Lung Squamous Cell Carcinoma. PubMed 42711990
- Cancer Immunol Immunother, 2026 (senior author): Macrophage heterogeneity in breast cancer microenvironment and development of a prognostic model: exploring TFF1 as a novel therapeutic target. PubMed 42400645
- Biochim Biophys Acta Rev Cancer, 2026 (senior author): Immunotherapy in EGFR-TKI-resistant NSCLC: Mechanisms, therapeutic strategies, and emerging challenges. PubMed 41702448
- Front Oncol, 2025 (senior author): The pathogen's playbook in cancer: from oncogenesis to progression. PubMed 41607541
- Cancer Biol Med, 2025 (senior author): Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy. PubMed 41369248
- Front Immunol, 2025 (senior author): Immune checkpoint inhibitors for extensive-stage small-cell lung cancer: a network meta-analysis and cost-effectiveness analysis. PubMed 41221276
- Talanta, 2025 (senior author): A novel photosensitive nanoprobe combined with CRISPR/Cas12a for dual signal amplification detection of ANGPTL2. PubMed 40147084
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion